Remdesivir demand was exaggerated: Dr. Sharvil Patel
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
The drug will target specific genetic mutations prevalent in certain types of cancers
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
Methylene blue is a cationic thiazine dye that necessitates specialised capabilities and expertise to develop and manufacture the product
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
Zydus' Indomethacin suppositories also been granted 180-day CGT exclusivity to market this product.
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
Subscribe To Our Newsletter & Stay Updated